GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Cyclically Adjusted PB Ratio

GeneThera (GeneThera) Cyclically Adjusted PB Ratio : (As of May. 24, 2024)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


GeneThera Cyclically Adjusted PB Ratio Historical Data

The historical data trend for GeneThera's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Cyclically Adjusted PB Ratio Chart

GeneThera Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GeneThera Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GeneThera's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, GeneThera's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneThera's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GeneThera's Cyclically Adjusted PB Ratio falls into.



GeneThera Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GeneThera's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, GeneThera's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.242/125.2265*125.2265
=-0.242

Current CPI (Sep. 2022) = 125.2265.

GeneThera Quarterly Data

Book Value per Share CPI Adj_Book
201212 -0.176 96.871 -0.228
201303 -0.177 98.209 -0.226
201306 -0.181 98.518 -0.230
201309 -0.164 98.790 -0.208
201312 -0.168 98.326 -0.214
201403 -0.174 99.695 -0.219
201406 -0.175 100.560 -0.218
201409 -0.166 100.428 -0.207
201412 -0.167 99.070 -0.211
201503 -0.159 99.621 -0.200
201506 -0.164 100.684 -0.204
201509 -0.172 100.392 -0.215
201512 -0.179 99.792 -0.225
201603 -0.177 100.470 -0.221
201606 -0.173 101.688 -0.213
201609 -0.179 101.861 -0.220
201612 -0.178 101.863 -0.219
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 -0.180 104.011 -0.217
201803 -0.186 105.290 -0.221
201806 -0.187 106.317 -0.220
201809 -0.195 106.507 -0.229
201812 -0.179 105.998 -0.211
201903 -0.226 107.251 -0.264
201906 -0.230 108.070 -0.267
201909 -0.229 108.329 -0.265
201912 -0.193 108.420 -0.223
202003 -0.197 108.902 -0.227
202006 -0.203 108.767 -0.234
202009 -0.313 109.815 -0.357
202012 -0.320 109.897 -0.365
202103 -0.307 111.754 -0.344
202106 -0.279 114.631 -0.305
202109 -0.261 115.734 -0.282
202112 -0.241 117.630 -0.257
202203 -0.244 121.301 -0.252
202206 -0.239 125.017 -0.239
202209 -0.242 125.227 -0.242

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GeneThera  (OTCPK:GTHR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GeneThera Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of GeneThera's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines